Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.44 |
| ▸ | MASP2 | O00187 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 6/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 2/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8067762 | 1.00 | MAPT (0.50) | MAPTSMYD3GAAMTNR1AMASP2 | |
| SCHEMBL1268909 | 0.90 | SMYD3 (0.59) | MAPTSMYD3GAAMTNR1AMASP2 | |
| SCHEMBL17675115 | 0.85 | MAPT (0.65) | MAPTSMYD3GAAMTNR1AMME | |
| SCHEMBL8791310 | 0.84 | MAPT (0.50) | MAPTSMYD3GAAMTNR1AMME | |
| SCHEMBL8790874 | 0.81 | MAPT (0.47) | MAPTSMYD3GAAMTNR1AF2 | |
| SCHEMBL25937486 | 0.80 | SMYD3 (0.53) | MAPTSMYD3GAAMTNR1AMASP2 | |
| SCHEMBL2266601 | 0.80 | GAA (0.71) | MAPTSMYD3GAAMTNR1AMASP2 | |
| SCHEMBL10742930 | 0.80 | GAA (0.71) | MAPTSMYD3GAAMTNR1AMASP2 | |
| SCHEMBL30900484 | 0.80 | GAA (0.71) | MAPTSMYD3GAAMTNR1AMASP2 | |
| Hydrochloric Acid SCHEMBL28262901 | 0.78 | GAA (0.69) | MAPTSMYD3GAAMTNR1AMASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564547-B2 | Compositions, formulations, and methods for skin treatment | ODDITY LABS, LLC (US) | 2026-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564547-B2 | Compositions, formulations, and methods for skin treatment | MCOLN1, H1-0, APOL1 | MAPT 3212/4885SMYD3 1469/4885GAA 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.